SCHEMBL3110282

SCHEMBL3110282

NS(=O)(=O)c1ccc(-n2nc(CN3CC=CCC3)nc2Cc2cccc(F)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 8/20 0.39
CA1 P00915 5/20 0.38
CA2 P00918 5/20 0.38
CA9 Q16790 4/20 0.38
NTRK1 P04629 2/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
PDPK1 O15530 1/20 0.36
PTGS1 P23219 2/20 0.35
CA12 O43570 2/20 0.34
CA7 P43166 2/20 0.34
CA14 Q9ULX7 1/20 0.34
HTR6 P50406 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115566 0.92 CA1 (0.35) PTGS2CA1CA2CA9PDPK1
SCHEMBL3112892 0.90 CA1 (0.44) PTGS2CA1CA2CA9PTGS1
SCHEMBL3114770 0.90 PTGS2 (0.39) PTGS2CA1CA2CA9PDPK1
SCHEMBL3115250 0.90 PTGS2 (0.39) PTGS2CA1CA2CA9PDPK1
SCHEMBL3104565 0.89 CA1 (0.41) PTGS2CA1CA2CA9PDPK1
SCHEMBL3111507 0.89 CA1 (0.43) PTGS2CA1CA2CA9PDPK1
SCHEMBL3112965 0.89 CA1 (0.39) PTGS2CA1CA2CA9PDPK1
SCHEMBL3098291 0.87 ADORA2A (0.39) PTGS2CA1CA2CA9PDPK1
SCHEMBL3101694 0.84 CA1 (0.40) PTGS2CA1CA2CA9PTGS1
SCHEMBL3102947 0.84 PTGS2 (0.37) PTGS2CA1CA2CA9PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
WO-2008017932-A2 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE PFIZER PRODUCTS INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE CA2, CA7, CA9 PTGS2 47/4885CA1 7/4885CA2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.